Phibro Animal Health (PAHC) Total Non-Current Liabilities (2013 - 2026)
Phibro Animal Health (PAHC) posted quarterly Total Non-Current Liabilities of $1.1 billion for Q1 2026, up 4.13% year-over-year from $1.0 billion in Q1 2025, and up 1.82% quarter-over-quarter from $1.1 billion in Q4 2025.
Phibro Animal Health (PAHC) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Phibro Animal Health's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 4.13% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 4.13% YoY), while the FY2025 annual figure was $995.9 million, up 38.57% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.1 billion in Q1 2026, with the low at $608.8 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $694.8 million (2023), against an average of $798.6 million.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities dropped 1.89% in 2023, then surged 61.08% in 2025.
- Phibro Animal Health's Total Non-Current Liabilities stood at $684.3 million in 2022, then advanced by 1.53% to $694.8 million in 2023, then jumped by 47.81% to $1.0 billion in 2024, then grew by 3.48% to $1.1 billion in 2025, then advanced by 1.82% to $1.1 billion in 2026.
- Business Quant data shows PAHC's Total Non-Current Liabilities at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $994.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Phibro Animal Health | 1.47 Bn | 1.39 Bn | 125.68 Mn | 994.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 994.66 Mn |
| Jun 30, 2025 | 995.91 Mn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 1.03 Bn |
| Sep 30, 2024 | 701.27 Mn |
| Jun 30, 2024 | 718.70 Mn |
| Mar 31, 2024 | 645.08 Mn |
| Dec 31, 2023 | 694.77 Mn |
| Sep 30, 2023 | 685.36 Mn |
| Jun 30, 2023 | 682.81 Mn |
| Mar 31, 2023 | 631.32 Mn |
| Dec 31, 2022 | 684.29 Mn |
| Sep 30, 2022 | 679.71 Mn |
| Jun 30, 2022 | 608.76 Mn |
| Mar 31, 2022 | 643.51 Mn |
| Dec 31, 2021 | 553.95 Mn |
| Sep 30, 2021 | 546.60 Mn |
| Jun 30, 2021 | 546.83 Mn |